Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 1, 2008, Pages 36-45

  Louis, Caroline ^a   Stemmelin, Jeanne ^a   Boulay, Denis ^a   Bergis, Olivier ^a   Cohen, Caroline ^a   Griebel, Guy ^a  

^a SANOFI   (France)

Author keywords

Animal models; Anxiety; Depression; Neurokinin 2; Rodents; Saredutant

Indexed keywords

BUSPIRONE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; NEUROKININ 2 RECEPTOR ANTAGONIST; SAREDUTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL MODEL; FEMALE; MALE; NEWBORN; NONHUMAN; OLFACTORY BULBECTOMY; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PSYCHOLOGICAL MODEL; RAT; REINFORCEMENT; SEPARATION ANXIETY; SOCIAL INTERACTION; STRESS; TRANQUILIZING ACTIVITY; ULTRASOUND;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY, SEPARATION; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZAMIDES; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; FEMALE; IMIPRAMINE; MALE; MICE; MICE, INBRED BALB C; OLFACTORY BULB; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, NEUROKININ-2; REINFORCEMENT SCHEDULE; SOCIAL ISOLATION; VOCALIZATION, ANIMAL;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 38049103986     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.10.020     Document Type: Article

References (51)

1. Alonso R., Griebel G., Pavone G., Stemmelin J., Le Fur G., and Soubrié P. Blockade of CRF1 of V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 9 (2004) 278-286
2. Balcells-Olivero M., Cousins M.S., and Seiden L.S. Holtzman and Harlan Sprague-Dawley Rats: differences in DRL 72-sec performance and 8-hydroxy-di-propylaminotetralin-induced hypothermia. J Pharmacol Exp Ther 286 (1998) 742-752
3. Britton K.T., and Koob G.F. Effects of corticotropin releasing factor, desipramine and haloperidol on a DRL Schedule of reinforcement. Pharmacol Biochem Behav 32 (1989) 967-970
4. Broekkamp C.L., Garrigou D., and Lloyd K.G. Serotonin-mimetic and antidepressant drugs on passive avoidance learning by olfactory bulbectomized rats. Pharmacol Biochem Behav 13 (1980) 643-646
5. Buell G., Schulz M.F., Arkinstall S.J., Maury K., Missotten M., Adamin N., et al. Molecular characterization, expression and localization of human neurokinin-3 receptor. FEBS Lett 299 (1992) 90-95
6. Cairncross K.D., Cox B., Forster C., and Wren A.F. Olfactory projection systems, drugs and behavior: a review. Psychoneuroendocrinology 4 (1979) 253-272
7. Cohen C., Perrault G., and Sanger D.J. Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol 8 (1997) 629-638
8. Dableh L.J., Yashpal K., Rochford J., and Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507 (2005) 99-105
9. Dekeyne A., Gobert A., Auclair A., Girardon S., and Millan M.J. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology 162 (2002) 156-167
10. De Lima T.C.M., Teixeira R.M., Santos A.R.S., Rae G.A., and Calixto J.B. Behavioral effects of intracerebroventricular injection of selective tachykinin agonists and antagonists (1995) 1696
11. Ducottet C., Griebel G., and Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuro-psychopharmacol Biol Psychiatry 27 (2003) 625-631
12. Duggan A.W., and Furmidge L.J. Probing the brain and spinal cord with neuropeptides in pathways related to pain and other functions. Front Neuroendocrinol 15 (1994) 275-300
13. Emonds-Alt X., Vilain P., Goulaouic P., Proietto V., Van Broek D., Advenier C., et al. A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci 50 (1992) PL101-PL106
14. File S.E., and Hyde J.R. Can social interaction be used to measure anxiety?. Br J Pharmacol 62 (1978) 19-24
15. Garrigou D., Broekkamp C.L., and Lloyd K.G. Involvement of the amygdala in the effect of antidepressants on the passive avoidance deficit in the bulbectomized rat. Psychopharmacology (Berl) 74 (1981) 66-70
16. Gerard N.P., Eddy Jr. R.L., Shows T.B., and Gerard C. The human neurokinin A (substance K) receptor. J Biol Chem 265 (1990) 20445-20462
17. Gerard N.P., Garraway L.A., Eddy Jr. R.L., Shows T.B., Iijima H., Paquet J.L., et al. Human substance P receptor (NK-1): organization of the gene, chprmosome localization, and functional expression of cDNA clones. Biochemistry 30 (1991) 10640-10646
18. Griebel G., Moindrot N., Aliaga C., Simiand J., and Soubrié P. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev 25 (2001) 619-626
19. Griebel G., Perrault G., and Soubrié P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158 (2001) 241-251
20. Hagan R.M., Beresford I.J.M., Stables J., Dupere J., Stubbs C.M., Elliott P.J., et al. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regul Pept 46 (1993) 9-19
21. Jolly D.C., Richards J.B., and Seiden J.S. Serotonergic mediation of DRL 72s behavior: receptor subtype involvement in behavioral screen for antidepressant drugs. Biol Psychiatry 49 (1999) 1151-1162
22. Joly D., and Sanger D.J. The effects of fluoxetine and zimeldine on the behavior of olfactory bulbectomized rats. Pharmacol Biochem Behav 24 (1986) 199-204
23. Kelly J.P., Wrynn A.S., and Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74 (1997) 299-316
24. Louis C., Cohen C., Depoortere R., and Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72s schedule in the rat. Neuropsychopharmacology 31 (2006) 2180-2187
25. Maggi C.A. The mammalian tachykinin receptors. Gen Pharmacol 26 (1995) 911-944
26. Maggi C.A., Patacchini R., Giuliani S., and Giachetti A. In vivo and vitro pharmacology of SR 48,968, a non-peptide tachykinin NK2 receptor antagonist. Eur J Pharmacol 234 (1993) 83-90
27. Noreika L., Pastor G., and Liebman J. Delayed emergence of antidepressant efficacy following withdrawal in olfactory bulbectomized rats. Pharmacol Biochem Behav 15 (1981) 393-398
28. O'Donnell J.M., and Seiden L.S. Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther 224 (1983) 80-88
29. Otsuka M., and Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73 (1993) 229-308
30. Regoli D., Boudon A., and Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46 (1994) 551-599
31. Richards J.B., and Seiden L.S. A quantitative interresponse-time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone. J Exp Anal Behav 56 (1991) 173-192
32. Richards J.B., Sabol K.A., and Seiden L.S. DRL interresponse-time distributions:quantification by peak deviation analysis. J Exp Anal Behav 60 (1993) 361-385
33. Richardson J.S., and Tiong A.H.K. Amygdaloid and hippocampal b-adrenoreceptors in the olfactory bulbectomy syndrome: effects of desipramine. Ann N Y Acad Sci 877 (1999) 764-768
34. Risbrough V.B., and Stein M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 50 (2006) 550-561
35. Saffroy M., Torrens Y., Glowinski J., and Beaujouan J.C. Presence of NK2 binding sites in the rat brain. J Neurochem 79 (2001) 985-996
36. Saffroy M., Torrens Y., Glowinski J., and Beaujouan J.C. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 116 (2003) 761-773
37. Salomé N., Stemmelin J., Cohen C., and Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 83 (2006) 533-539
38. Sergeyev V., Fetissov S., Mathe A.A., Jimenez P.A., Bartfai T., Mortas P., et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berl) 178 (2005) 115-124
39. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharmacol Rev 54 (2002) 285-322
40. Shirayama Y., Mitsushio H., Takashima M., Ichikawa H., and Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739 (1996) 70-78
41. Song C., and Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29 (2005) 627-647
42. Song L., Che W., Min-Wei W., Murakami Y., and Matsumoto K. Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 83 (2006) 186-193
43. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299 (2001) 449-458
44. Stratton S.C., Beresford I.J.M., Elliott P.J., and Hagan R.M. Behavioural effects of centrally infused tachykinin NK2 receptor agonists and antagonists in rat models of anxiety. J Psychopharmacol 7 (1993) A11
45. Stratton S.C., Beresford I.J.M., Harvey F.J., Turpin M.P., Hagan R.M., and Tyers M.B. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol 250 (1993) R11-R12
46. Stratton S.C., Beresford I.J.M., and Hagan R.M. GR159897, a potent non-peptide tachykinin NK2 receptor antagonist, releases suppressed behaviours in a novel aversive environment. Br J Pharmacol 112 (1994) 49P
47. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., and De Lima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311 (1996) 7-14
48. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20 (2000) 4030-4036
49. van Riezen H., Schnieden H., and Wren A.F. Olfactory bulb ablation in the rat: behavioural changes and their reversal by antidepressant drugs. Br J Pharmacol 60 (1977) 521-528
50. Walsh D.M., Stratton S.C., Harvey F.J., Beresford I.J.M., and Hagan R.M. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121 (1995) 186-191
51. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16 (1992) 525-534